Category Archives: Hypertension

Global Pulmonary Arterial Hypertension Market Report Forecast 2028 states overview of epidemiology trends of Pulmonary Arterial Hypertension Industry. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Pulmonary Arterial Hypertension and contains the targeted patient populations as well as forecast methodology Continue reading →

New data analysis of the ongoing French Cohort of Myocardial Infarction Evaluation (FRENCHIE) registry reveals a decline in hospital admission for acute myocardial infarction following the coronavirus disease 2019 (COVID-19) lockdown. Although the reasons for such findings can only be speculative, the investigators noted that this marked decrease should encourage public health officials to provide appropriate messages that especially target those that are wary of utilizing health services during the pandemic Continue reading →

Multiple cancer treatments, such as regimens that include anthracyclines and molecular targeted therapies, can cause cardiotoxicities. Patients who are at high risk for these dangerous adverse events (AEs) need to be identified and managed appropriately by educating everyone involved in the patients care and establishing collaboration between medical oncologists and cardiologists Continue reading →

Written by Dan Gray on September 10, 2020 Fact checked by Dana K. Cassell New research is reporting that uncontrolled high blood pressure is a growing problem among adults in the United States. The findings were presented this week at the virtual American Heart Associations Hypertension Scientific Sessions 2020. Continue reading →

Sept. 9, 2020, 9:50 PM UTC/Updated Sept Continue reading →

In Burkina Faso, around 1.5 million people have or are at high risk of heart disease. Cardiovascular disease (CVD) is responsible for around one-in-three deaths - approximately 20,600 each year - and more than from any other NCD. Continue reading →

Oral combination therapy does not appear to help achieve or maintain low risk status in most treatment-naive patients with pulmonary arterial hypertension (PAH), according to the results of a recent study published in the American Journal of Respiratory and Critical Care Medicine. Treatment-naive patients with PAH received combination oral therapy consisting of endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE-5i) medications Continue reading →

Racial and ethnic minoritized populations bear a disproportionate burden of illness and death as the COVID-19 pandemic continues in the U.S. These inequities are caused by larger determinants of health, such as lack of access to care, cultural bias in clinical decisions, structure of delivery systems, and structural racism. To begin to tackle inequities in care, health systems and medical groups must understand whom they are serving, the collection of accurate sociodemographic data, such as race and ethnicity data is critical Continue reading →

Nighttime nasal high flow therapy (NHF) at 20 L/min reduced sympathetic drive, most likely through washout of anatomical dead space, in patients with precapillary pulmonary hypertension (PH) and obstructive sleep apnea (OSA), according to study results published in Sleep and Breathing. Pharmacologic treatment of PH may restore sympathovagal balance (SVB), at least partially. Continue reading →

The report is an all-inclusive research study of the global Pulmonary Arterial Hypertension Treatment market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Pulmonary Arterial Hypertension Treatment market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario Continue reading →